All In Biotech

Drug Trial Radar · NCT03097107

Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL

Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL

Last checked: Nov 20, 2026Latest source record: Feb 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

SuspendedPivotal-lookingRandomized with 124 participants. This is a heuristic, not a regulatory label.

Status

Suspended

Enrollment

124

Planned (sponsor's estimate)

Start

Apr 6, 2017

Primary completion

Dec 2023

Study completion Jan 2024

Sponsor

Lead sponsor
Zydus Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Mar 31, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and efficacy of Saroglitazar Magnesium 1, 2, and 4 mg in patients with fasting triglyceride ≥500 mg/dL and ≤1500 mg/dL.

Conditions

  • Dyslipidemias

Interventions

  • Saroglitazar Magnesium 1 mgDrug

    Randomly assigned patients will receive saroglitazar magnesium 1 mg orally once each morning before breakfast for 12 weeks

  • Saroglitazar Magnesium 2 mgDrug

    Randomly assigned patients will receive saroglitazar magnesium 2 mg orally once each morning before breakfast for 12 weeks

  • Saroglitazar Magnesium 4 mgDrug

    Randomly assigned patients will receive saroglitazar magnesium 4 mg orally once each morning before breakfast for 12 weeks

  • PlaceboDrug

    Randomly assigned patients will receive placebo orally once each morning before breakfast for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in triglyceride cholesterol levelsTime frame: 12 Weeks

Locations

33 sites in 1 country. Site status is shown where the registry gives one.

  • Medical Affiliated Research Center, Inc.

    Huntsville, Alabama

  • Encompass Clinical Research

    Encinitas, California

  • Integrated Research Center

    San Diego, California

  • Ventura Clinical Trials

    Ventura, California

  • Colorado Springs Health Partners

    Colorado Springs, Colorado

  • Meridien Research - Bradenton

    Bradenton, Florida

  • Meridien Research - Lakeland

    Lakeland, Florida

  • Oviedo Medical Research, LLC

    Oviedo, Florida

  • Meridien Research - Tampa

    Tampa, Florida

  • River Birch Research Alliance LLC

    Blue Ridge, Georgia

  • Drug Studies America

    Marietta, Georgia

  • Herman Clinical Research, LLC

    Suwanee, Georgia

  • Cedar-Crosse Research Center

    Chicago, Illinois

  • Heartland Research Associates, LLC

    Newton, Kansas

  • Heartland Research Associates, LLC

    Wichita, Kansas

  • University of Maryland Medical Center

    Baltimore, Maryland

  • Centennial Medical Group

    Elkridge, Maryland

  • MD Medical Research

    Oxon Hill, Maryland

  • Mercury Street Medical

    Butte, Montana

  • Einstein Clinical Research

    Charlotte, North Carolina

  • Triad Clinical Trials LLC

    Greensboro, North Carolina

  • PMG Research of Wilmington, LLC

    Wilmington, North Carolina

  • Metabolic and Atherosclerosis Research Center

    Cincinnati, Ohio

  • Sterling Research Group, Ltd.

    Cincinnati, Ohio

  • Wells Institute for Health Awareness

    Kettering, Ohio

  • Ohio Clinical Research - Lyndhurst

    Lyndhurst, Ohio

  • Awasty Research Network, LLC

    Marion, Ohio

  • Ohio Clinical Research, LLC - Willoughby Hills

    Willoughby Hills, Ohio

  • Columbia Research Group, Inc.

    Portland, Oregon

  • PMG Research of Bristol, LLC

    Bristol, Tennessee

  • Jackson Clinic

    Jackson, Tennessee

  • Pioneer Research Solutions Inc.

    Houston, Texas

  • National Clinical Research - Richmond, Inc

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.